UTI UNIVERSAL TECHNICAL INSTITUTE INC Insider Trading

CEO Jerome Alan Grant sells 94,500 shares (22.0% of holdings) at blended $41.40; stock now $42.77, up 14.3% in 30 days.

Jerome Alan Grant, Chief Executive Officer of Universal Technical Institute, executed 2 separate sales totaling 94,500 shares for $3,912,306.29 on 2026-06-29, reducing his holdings from 430,215 shares to 335,715 shares. The sales occurred at a blended average price of $41.40, while the current price is $42.77, and the stock has posted a 30-day return of +14.3% following the transaction. Across his prior 3 sales at UTI, the insider achieved a 90-day well-timed rate of 33.33%, meaning only 1 of his prior 3 UTI sales were followed by stock declines—a notably low accuracy rate. The company trades at a P/E of 54.83 with recent quarterly revenue of $221,402,000.00 and annual revenue growth of +14.0%, but net income of only $433,000.00 signals a significant margin compression despite top-line expansion.

Coliseum Capital Management (Director) sold 3,000,000 shares of UTI at $41.40 on 2026-06-08, reducing stake from 3.97M to 971.4K shares (-75.5%).

Coliseum Capital divested a substantial 3,000,000 shares (75.5% of pre-transaction holdings) for $124,200,000.00, leaving a material but minority position of 971.4K shares. The sale occurred at $41.40, above the current price of $39.75 and above the 52-week low of $21.29, though -13.1% from the 52-week high of $45.74. Notably, the insider's prior two buys at UTI (2025-12-03 and 2025-12-05) both generated strong 90-day returns (+52.9% and +38.2% respectively), establishing a pattern of well-timed entry points at this ticker. This large sale, executed after two successful accumulations, represents a material reduction in conviction and should be monitored given the stock's elevated valuation (P/E 50.96) relative to modest recent profitability ($433.0K net income on $221.4M quarterly revenue).

Chief Legal Officer sold 23.7K shares of UTI at $37.55; prior pattern shows 100% well-timed sells at 90-day horizon

Kevane Christopher E., EVP and Chief Legal Officer, sold 23,654 shares at $37.55 on 2026-03-27, reducing his holdings by -22.1% to 83,521 shares. His prior sales at UTI (both on 2025-05-12) demonstrated consistent positive timing: the first showed -21.3% 90-day return, the second -24.2% 90-day return, indicating the stock declined after he sold both times. His cross-ticker track record reinforces this pattern, with a 90d well-timed rate of 100.00% across 2 prior sells. The current price of $36.10 is now -9.0% from the 52-week high of $39.66, and only -0.3% below where he executed this sale 30 days ago, suggesting the timing signal remains an open question at the intermediate horizon.

EVP/COO Hitchcock Todd A sold 16,500 shares of UTI at $37.33 for $615,945.00 on 2026-03-04; stock at $34.99 now

Hitchcock Todd A, EVP/COO, executed a discretionary open-market sale of 16,500 shares representing -13.7% of pre-transaction holdings, completing the transaction at $37.33, which was near the 52-week high of $37.50. Notably, his prior two sales at UTI (both on 2025-05-15) demonstrated strong 90-day timing, with each followed by negative returns of -22.7% and -23.8%, establishing a pattern of selling ahead of declines. His cross-ticker track record shows a 100.00% well-timed rate across 2 prior open-market sells. The current price of $34.99 represents a -6.7% pullback from the 52-week high and a decline since the transaction date, consistent with his established selling pattern. The company's strong fundamentals (revenue growth of +14.0% annually, net income of $12,827,000.00, and a P/E of 35.70) suggest the timing reflects market positioning rather than fundamental deterioration.

EVP Smith Sherrell sells 50,000 UTI shares at $33.84 (-6.7% from 52-week high, after +37.2% 90-day rally)

Smith Sherrell, Chief Academic Officer, sold 50,000 shares (54.8% of his pre-transaction holdings) at $33.84 on 2025-05-12, reducing his stake from 91,219 to 41,219 shares. The sale occurred after UTI stock gained 37.2% over 90 days and 25.6% over 30 days, with the transaction price 6.7% below the 52-week high of $37.50. His prior trades at UTI (three measurable sales: 2025-03-19, 2025-03-19, 2025-03-20) were followed by positive 90-day returns (+19.1%, +19.1%, +24.7%), indicating a pattern of selling before subsequent gains rather than before declines. His cross-ticker sell history shows a 0.00% well-timed rate with an average 90-day return of +23.0%, suggesting his sales have historically not preceded price weakness. The company's fundamentals remain solid: $220.8M quarterly revenue, +14.0% annual growth, and a P/E of 35.70 on a $1.9B market cap.

UTI's Chief Academic Officer sells 52,671 shares for $1,951,021.39; reduces stake 58.4% at $37.04 blended average.

Smith Sherrell executed 2 separate sales totaling 52,671 shares for $1,951,021.39 on 2026-03-02, reducing his post-transaction holdings to 37,474 shares—a 58.4% reduction from the pre-transaction 90,145 shares. The blended average sale price of $37.04 sits near the 52-week high of $37.50 and represents a 3.4% premium to the current price of $35.82, which has risen 23.6% over the past 30 days and 37.4% over 90 days. Across Sherrell's prior trades at UTI specifically, only 1 of 5 prior sells registered a negative 90-day return (well-timed), indicating limited historical precision in his sale execution at this ticker. The company's fundamentals remain solid—revenue of $220,844,000.00, net income of $12,827,000.00, and annual growth of 14.0%—though the P/E of 36.55 reflects elevated valuation; the substantial reduction in holdings merits monitoring alongside recent strong price momentum.

CEO Grant Jerome Alan sold 60,040 shares of UTI at $34.95 on 2026-02-27 for $2.1M; stock now at $37.40 (+0.0% from 52-week high).

CEO Grant Jerome Alan sold 60,040 shares (60.0K shares) for $2,098,494.06 ($2.1M), reducing his holdings from 490,255 shares to 430,215 shares, a reduction of 12.2% of his pre-transaction holdings. The sale occurred at $34.95 while the current price is $37.40, indicating the stock has appreciated $2.45 per share (7.0%) since the transaction. His cross-ticker track record shows 2 prior sells with an average 90-day return of +7.1%, suggesting his prior sales were generally poorly timed; his same-ticker history at UTI includes 1 well-timed sale (2024-08-23 with 90d +34.6%) and 1 poorly timed sale (2025-05-12 with 90d -20.5%), yielding a 50% well-timed rate at this ticker. The company's fundamentals show annual revenue growth of +14.0% with a P/E of 38.16, indicating a premium valuation despite solid growth.

Coliseum Capital buys 547,066 shares in 3 transactions for $13.7M; holdings rise 16.0% to 3.97M shares at avg $25.01

Coliseum Capital Management, LLC executed 3 separate purchases totaling 547,066 shares for $13,682,697.99 between December 1-5, 2025, raising its stake by 16.0% from 3.42M to 3.97M shares at a blended average price of $25.01. The timing occurs as the stock trades at $25.50 (current price), down 29.0% from its 52-week high of $35.90 and down 9.3% over the past 30 days. The company's fundamentals show solid positioning: annual revenue growth of 14.0%, P/E of 16.45, and net income of $10.7M on $204.3M in quarterly revenue. Notably, this insider has a strong cross-ticker track record with a 92.31% win rate on 17 prior buys (average 90-day return +47.4%), though same-ticker history at UTI is nascent with only 3 prior measurable trades initiated just 1-2 days before this filing and outcomes not yet measurable.

Coliseum Capital Management (Director) purchased 708,107 shares across 3 transactions for $17,130,752.07 at UTI, increasing holdings by 26.1%

Coliseum Capital Management executed 3 separate purchases totaling 708,107 shares (708.1K shares) for $17,130,752.07 ($17.1M) on 2025-12-01 and 2025-12-02 at a blended average price of $24.19, expanding its stake from 2,716,267 shares (2.72M shares) to 3,424,374 shares (3.42M shares). The transaction occurred while the stock trades at $25.01, -30.3% from its 52-week high of $35.90 and down 12.2% over the past 30 days. UTI's fundamentals show revenue of $204,298,000.00 ($204.3M) in the latest quarter, net income of $10,663,000.00 ($10.7M), and annual revenue growth of +14.0%, with a P/E of 16.14. The director's cross-ticker track record shows 17 prior buys with an average 90-day return of +47.4% and a 90% win rate, though same-ticker outcomes are not yet measurable; this represents a material capital commitment during a period of price weakness relative to recent highs.

UTI Director DeVincenzi purchases 10,000 shares for $253,990.88 across two transactions at $25.39–$25.40, raising stake 7.9%.

Director Robert Thomas DeVincenzi executed 2 separate purchases totaling 10,000 shares for $253,990.88 at a blended average price of $25.40 on 2025-08-12, increasing his holdings from 126,765 to 136,765 shares (+7.9%). The purchases occurred at prices near the current market level ($25.50) but represent a material position addition when the stock is trading -29.0% from its 52-week high and -20.1% over the prior 30 days. His cross-ticker track record shows 2 prior sells with a 90-day well-timed rate of 0.00%, and his 2 prior sales at UTI in November 2024 yielded positive 90-day returns (+4.2% and +2.0%), indicating neither was well-timed. The company reports robust fundamentals with $204.3M quarterly revenue, +20.6% annual growth, and a P/E of 21.98, providing a backdrop of operational strength that contextualizes the discretionary buy decision.